Τόμος 1 (1983) – Τεύχος 3 – Άρθρο 5 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 1 (1983) – Issue 3 – Article 5 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Cytotoxic Drugs and their Place in the Treatment of Malignant Neoplasias

George P. Stathopoulos

Stathopoulos, G.P.: Cytotoxic Drugs and their Place in the Treatment of Malignant Neoplasias, Epitheorese Klin. Farmakol. Farmakokinet. 3: 219-230 (1983)

Cytotoxic chemotherapy, cytotoxic drugs, pharmakokinetics

2.         Myers, M.H., Hankey, B.F., Sternhorn, S.C.: Update on mortality research: Long-Term conditional survival of cancer patients. In: Chiappetta, R.N., ed. Record Chicago: Illinois Society of Actuaries 1421 (1981)

3.         Bruce, W.R., Meeker, B.E., and Valeriote, F.A.: J. Nat. Cancer Inst. 37: 233 (1966)

4.         Skipper, H.E., Schabel, F.M., Jr, and Vilcox, W.S.: Experimental evaluation of potential anticancer agents XIII. On the criteria and kinetics associated with «curability» of experimental leukemia. Cancer Chemother. Rep. 35: 1 (1964)

5.         Mendelsohn, M.L.: Autoradiographic analysis of cell proliferation in spontaneous breast cancer of C3H mouse. The growth fraction. J. Natl. Cancer Inst. 28: 1015 (1962)

6.         Skipper, H.E.: Clowes Memorial Lecture. CancerRec. 31: 1173 (1971)

7.         Mellett, L.G.: The constancy of the product of concentration and time. In Sarlorelll, A.C., and Johns, D.G., (Eds) Antineoplastlc and Immusuppressive Agents. Part I. New York, Springer-Verlag. 330 (1974)

8.         Goldstein, A., Aronow, L., and Kalman, S.M.: Principles of drug Action: The Basis of Pharmacology 2nd ed. (1974)

9.         Chabner, B.A., Meyers, C.E., and Oliverio, V.T.: Clinical pharmacology of anticancer drugs. Semin. Oncol. 4: 165 (1977)

10.       Koch-Weser, J.: Drug therapy’ll bioavailability of drugs. N. Engl. J. Med. 291: 233, 503 (1974)

11.        Vesell, E.S.: Relationship between drug distribution and therapeutic effects in man. Ann. Rev. Pharmacol. 14: 249 (1974)

12.       Vallner, J.J.: Binding of drugs by albumin and plasma protein. J. Pharm. Sci. 66: 447 (1977)

13.       Bossi A., Colombo, T., Donelli, M.G., et al: Activity of cyclophosphamide and 1-methylnitrosourea on Ehrlich carrinoma transplanted in different sites. Correlation between drug level and tumour inhibition. Biochem. Pharmacol. 24: 21 (1975)

14.       Von Ardenne, V.M., and von Ardenne, A.: Pharmacokinetic aspects of tumor tissue impairment by cancerostatics. Arzneim. Forsch. 25: 863 (1975)

15.       Okumura, Κ., Lee, Ι.Ρ., and Dixon, R.L.: Permeability of selected drugs and chemicals across the blood-testis barrier of the rat. J. Pharmacol. Exp. Thar. 194: 89 (1975)

16.       Oldendort, W.H.: Transport of drugs across the bloodbrain barrier. An. Rev. Pharmacol. 14: 239 (1974)

17.       Mellet, L.8.: Physicochemical consideration and pharmacokinetic behavior in delivery of drugs to the central nervous system. Cancer Treat. Rep. 61: 527 (1977)

18.       Johns, D.G.: Metabolism of cancer chemotherapeutic agents via pathways utilized by endogenous substrates. In Sartorelli, A.C., and Johns, D.G., (Eds), Antineopiastic and Immunosuppressive Agents Part I. New York, Springer Veriag. 270 (1974)

19.       Connors, T.A.: Bioactivation and cytotoxicity. Chapter 2. pp. 41-75 (1975)

20.      Benjamin, R.S., Wiernik, P.H., Bachur, N.R.: Adriamycin chemotherapy-efficacy. Safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 33: 19 (1974)

21.       Raisfald, I.H.: Chinical Pharmacology of drug interactions. Ann. Rev. Med. 24:385 (1973)

22.       Apple, M.A.: Avoiding drug interactions in anticancer drug therapy. Drug Ther. 5: 203 (1975)

23.       Zaharko, D.S., Bruekner, H., and Oliverio, V.T.: Antibiotics after methotrexate metabolism and excretion. Science 166: 887 (1969)

24.       Dixon, R.L., Henderson, E.S., and Rail, D.D.: Plasma protein binding of methotrexate and its displacement by various drugs. Fed. Proc. 24: 454 (1965)

25.       Capizzt, R.L., Keiser, L.W., Sartorelli, A., C.: Combination chemotherapy-theory and practice. Semin. Oncol. 4: 227 (1977)

26.       Curman, G.M.: Prolonged apnea after succinyl-choline in a case treated with cytostatistics for cancer. Anesth. Analg.’SI: 761 (1972)

27.       Calabresi, P., Parks, R.E., Jr.: Alkylating agents, antimetabolites, hormones, and other antiproliferative agents. In Goodman, L.S., and Gilman, A., (Eds): The pharmacological Basis of therapeutics 3rd Ed. New York. The MacMillan Company p. 1254 (1975)

28.      Brockman, R.W.: Mechanisms of resistance. In Sartorelli, A.C., and Johns, D.G., (Eds). Antineopiastic and Immunosuppressive A^enfs Part I. New York., Springer Veriag p. 352 (1974)

29.       Cadman, E.: Toxicity of chemotherapeutic agents. In Sartorelli, A.C., and Johns, D.G., (Eds), Antineopiastic and Immunosuppressive Agents. Part. I. New York, Springer-Verlag p. 59 (1974)

30.      Wheeler, G.P.: Alkylating agents. In Holland, J.F., and Frei, E. Ill (Eds): Cancer Medicine. Philadelphia, Lea and Febiger, p. 791 (1973)

31.       Van Duren, B.L: Biological effects of alkylating agents. Ann. NY Acad. Sci. 163: 589 (ed) (1969)

32.       Shealy, Y.F., Struck, R.F., Holum, L.B., and Montgomety, J.A.: Synthesis of potential anticancer agents. XXIX. 5-Diazoimidazole-4-carboxamide and 5-diazov-triazole-4-carboxamid. J. Org. Chem. 26: 2396 (1961)

33.       Shealy, Y.F., Krauth, C.A., and Montgomery, J.A.: Imidazoles. I., Coupling reactions of 5-diazoimidazole-4-carboxamide. J. Org. Chem. 27: 2150 (1962 a)

34.       Shealy, Y.F.: Synthesis and biological activity of 5-aminoimidazoles and 5-triazenoimidazoles. J. Pharm. Sci. 59: 1533 (1970)

35.       Proceedings of the Seventh New Drug Seminar: Nitrosoureas. Cancer Treat. Rep. 60: 645 (1976)

36.       Matthews, D.A., Alden, R.A., Bolin, J.T., et al.: Dihydrofolate reductase: x-rat structure of the binary complex with metrotrexate. Science 197: 452 (1977)

37.       Bleyer, W.A.: Methotrexate: Clinical pharmacology, current status and therapeutic guidelines. Cancer Treat. Rev. 4: 87 (1977)

38.      Goldman, I.D.: Analysis of the cytotoxic determinants for methotrexate (NSC-740): a role for «Free» intracellular drug. Cancer Che mo ther. Rep. (Part 3) 6: 51 (1975)

39.       Santi, D.V., McHenry, C.S., and Sommer, H.: Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13: 471 (1974)

40.      Wilkinson, D.S., Tisty, T.D., and Hanas, R.J.: The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine. Cancer Res. 35: 3014 (1975)

41.       Tidd, D.M., and Paterson, A.R.R.: A biochemical mechanism for the delayed cytotoxic reaection of 6-mercaptopurine. Cancer Res. 34: 738 (1974)

42.       Moore, E.C., and Lepage, G.A.: The metabolism of 6-thioguanine in normal and neoplastic tissues. Cancer Res. 18: 1075 (1958)

43.       Le Page, C.A., andWhitecar, J.P., Jr,: Pharmacology of 6-thioguanine in man. Cancer Res. 31: 1627 (1971)

44.       Chu, M.Y.: Incorporation of arabinosyl cytosine into S ribonucleic acid and cell death. Biochem. Rharmacol. 20: 2057 (1971)

45.       Momparler, R.L.: Kinetic and template studies with 1-β-D-arabinofuranosylcytosine 5′-triphosphate and mam-malian deoxyribonucleic acid polymerase. Mol. Pharmacol. 8: 362 (1972)

46.       Graham, F.L., and Whitmore, G.F.: Studies in mouse L-cells on the incorporation of DNA polymerase by 1 -β-D-arabinofuranosylcytosine S’-triphosphate. Cancer Res. 30: 2636 (1970)

47.       Kremer, W.B.: Cytarabine. Ann. Intern. Med., 82: 684 (1975)

48.      Cline, M.J.: Effect of vincristine on synthesis of ribonucleic acid protein in (eukaemic leukocytes. Brit.J. Haematol. 14: 21 (1968)

49.       Roodman, G.D., Hutton, J.J., Bollum, F.J.: DNA Polymerase activities during erythropoiesis. Effects of erythropoietin, vinblastine, colcemid, and daunomycin. Exp. Cell. Res. 91: 269 (1975)

50.       Proceedings of the Seventh New Drug Seminar: Nitrosoureas. Cancer Treat. Rep. 60: 645 (1976)

51.       Wilson, L., Bamburg, J.R., Mizel, S.B., et al: Interaction of drugs with microtubule proteins. Fed. Proc. 33: 158 (1974)

52.       Georgatsos, J.G., and Karemfyllts, T.: Action of podophyllic acid on malignant tumors-ll. Effects of podophyllic acid ethyl hydrazide on the incorporation of precursors into the nucleic acids of house mammary tumors and liver in vivo. Biochem. Pharmacol. 17: 1489 (1968)

53.       Stahelin, H.: 4-Demethyl-epippdophyIlotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action. Eur. J. Cancer 6: 303 (1970)

54.       Grieder, A., Maurer, R„ and Stahelin, H.: Effect of an epipodophyllotoxin derivative (VP 16-213) on macromolecuiar synthesis and mitosis in mastocytoma cells in vitro. Cancer Res. 34: 1783 (1974)

55.       DiMarco, A., Arcamone, F., Zunino, F.: Daunomycin (daunorubicin) and adriamycin and structural analogues: Biological activity and mechanism of action. In Corcoran, J.W., Hahn, F.E., (eds): Antibiotics vol. Ill: Mechanism of Action of Antimicrobial and Antitumor Agents. New York Springer-Verlag p. 101 (1975)

56.       Pater, M.M., and Mak, S.: Actinomycin D-Induced breakage of human KB cell DNA. Nature) London) 250: 786 (1974)

57.       Connors, T.A., Cox, P.J., Farmer, R.B., Foster, A.B., and Jarman, M.: Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem. Pharmacol. 23: 115 (1974)

58.       Newton, B.A: Adv. Pharmacol. Chemother. 8: 149 (1970)

59.       Goldberg, I.H., Rabinowitz, M.: Actinomycin D inhibition of deoxyribonucleic acid-dependent synthesis of ribonucleic acid. Science 136: 315 (1962)

60.      Szybalski, W., Iyer, V.N.: Cross-linking of DNA by enzymatically or chemically activated mitomycins and porfiromycin. Fed. Proc. Fed. Amer. Soc. Exp. Biot. 23:96 (1964)

61.       Ward, D.C., Reich, E., and Goldberg, I.H.: Base specificity in the interaction of polynueleotides with antibiotic drug. Science 149: 1259 (1965)

62.       Cerami, A., Reich, E.,, Ward, D.C., and Goldberg, I.H.: The interaction of actinomycin with DNA. Requirement for the 2-amino group of purines. Proc. Natl. Acad. Sci. U.S.A. 57: 1036 (1967)

63.       Suzuki, N., Kagai, K., Yamaki, H., Tanaka, H., and Umezawa, H,: Mechanism of action of bleomycin. Studies with the growing culture of bacterial and tumor cells. J. Antibiot. 21: 379 (1968)

64.       Müller, W.E.G., Totsuka, A., Nusser, l., Zahn, R.K., and Umezawa, H.: Bleomycin inhibition of DNA synthesis in isolated systems and in intact cell systems. Biochem. Pharmacol. 24: 911 (1975)

65.       DiCioccio, R., and Sahai Srivastava, B.I.: Effect of bleomycin on deoxynucleotide-polymerizing enzymes from human cells. Cancer Res. 36: 1664 (1976)

66.       Umezawa, H.: In cancer Medicine. Holland, J.F., and Frei, E. Ill (eds) Philadelphia. Lea and Febiger p, 81 7 (1973)

67.       Proceedings of the fifth new drug seminar: Adriamycin (Washington, D.C., December 16-17, 1974) and the Adriamycin New Drug Seminar (San Francisco, January 15-16, 1975). Cancer Chemother. Rep. Part 3, 6:83

68.      Sroder, L.E., and Carter, S.K.; Pancreatic islet cell carcinoma II. Results of therapy with streptozotocin in 52 patients. Ann. Intern. Med. 79: 108 (1973)

69.       Haskell, C.M., Canellos, G.P., Leventhal, B.G., et al.: L-Asparaginase-therapeutic and toxic effects in patients with neoplastic disease. N. Engl. J. Med. 281: 1028 (1969)

70.       Giraldi, T., and Taylor, D.M.: Biochem. Pharmacol. 23: 1659 (1974)

71.       Rosenberg, B.: Cisplatin: Its history and possible mechanisms of action. Cisplatin current status and new developments. Academic Press Inc. p. 9 (1980)

72.       Leh, F.K.V., and Wolf, W.: Platinum complexes: a new class of antineoplastic agents. J. Pharm. Sei. 65: 315 (1976)

73.       Frenkel, E.P., Arthur, C.: Induced ribotide reductive convers ion by hydroxyurea and its relationship to megaloblastosis. Cancer Res. 27: 1061 (1967)

74.       Martz, F., and Straw, J.A.: Treatment with o,p’-DDD (Mitotane) decreased cytochrome P-450, heme, and microsomal protein content in the dog adrenal cortex in vivo. Res. Conmun. Chem. Pathol. Pharmacol. 13: 83 (1976)

75.       Hart, M.M., Reagan, R.L., and Adamson, R.H.: The effect of isomers of ODD on the ACTHinduced steroid output, histology and ultrastruture of the dog adrenal cortex. Toxicol. Appl. Pharmacol. 24: 101 (1973)

76.       SpivacK, S.D.: Procarbazine. Arm. Intern. Med. 81: 795 (1971)